BR112020017481A8 - Derivados de di-hidrocromeno - Google Patents
Derivados de di-hidrocromenoInfo
- Publication number
- BR112020017481A8 BR112020017481A8 BR112020017481A BR112020017481A BR112020017481A8 BR 112020017481 A8 BR112020017481 A8 BR 112020017481A8 BR 112020017481 A BR112020017481 A BR 112020017481A BR 112020017481 A BR112020017481 A BR 112020017481A BR 112020017481 A8 BR112020017481 A8 BR 112020017481A8
- Authority
- BR
- Brazil
- Prior art keywords
- hydrogen atoms
- formula
- dihydrochromene
- derivatives
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
A presente invenção fornece um composto representado pela fórmula (I) ou seu sal farmacologicamente aceitável, o composto ou sal sendo útil como um novo agente antitumor que atinge CSC, que é sugerido estar significativamente envolvido no crescimento sustentado de tumores malignos, metástase de câncer, recorrência e resistência aos agentes antitumor. [Na fórmula, R1A, R1B, R1C e R1D são átomos de hidrogênio, R2A e R2B são átomos de hidrogênio, etc., R3A, R3B, R3C e R3D são átomos de hidrogênio, etc.; L representa uma ligação; V representa um C1-6 alquileno e Q representa um grupo imidazol opcionalmente substituído].
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-052971 | 2018-03-20 | ||
| JP2018052971 | 2018-03-20 | ||
| PCT/JP2019/011439 WO2019181939A1 (ja) | 2018-03-20 | 2019-03-19 | ジヒドロクロメン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112020017481A2 BR112020017481A2 (pt) | 2020-12-22 |
| BR112020017481A8 true BR112020017481A8 (pt) | 2022-12-06 |
Family
ID=67986459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020017481A BR112020017481A8 (pt) | 2018-03-20 | 2019-03-19 | Derivados de di-hidrocromeno |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10807993B2 (pt) |
| EP (1) | EP3770162B1 (pt) |
| JP (4) | JP6733072B2 (pt) |
| KR (1) | KR20200135401A (pt) |
| CN (1) | CN111886237A (pt) |
| AU (1) | AU2019239481B2 (pt) |
| BR (1) | BR112020017481A8 (pt) |
| CA (1) | CA3092255A1 (pt) |
| CY (1) | CY1126034T1 (pt) |
| DK (1) | DK3770162T3 (pt) |
| EA (1) | EA202092206A1 (pt) |
| ES (1) | ES2941771T3 (pt) |
| FI (1) | FI3770162T3 (pt) |
| HU (1) | HUE062256T2 (pt) |
| MX (1) | MX2020009763A (pt) |
| PH (1) | PH12020551497A1 (pt) |
| PL (1) | PL3770162T3 (pt) |
| PT (1) | PT3770162T (pt) |
| SG (1) | SG11202007979UA (pt) |
| TW (1) | TW201941774A (pt) |
| WO (1) | WO2019181939A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2941771T3 (es) * | 2018-03-20 | 2023-05-25 | Sumitomo Pharma Co Ltd | Derivados de dihidrocromeno |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001045707A1 (en) * | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20090111805A1 (en) * | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
| EP1847542A1 (en) * | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| CN101854802B (zh) * | 2007-09-10 | 2014-12-03 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| CA2990583A1 (en) | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
| CN107922348A (zh) * | 2015-06-22 | 2018-04-17 | 大日本住友制药株式会社 | 双环杂环酰胺衍生物 |
| US10898469B2 (en) * | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
| US20180127386A1 (en) * | 2016-10-20 | 2018-05-10 | Forma Therapeutics, Inc. | Methods using hdac11 inhibitors |
| ES2941771T3 (es) | 2018-03-20 | 2023-05-25 | Sumitomo Pharma Co Ltd | Derivados de dihidrocromeno |
| JP2020019752A (ja) * | 2018-08-03 | 2020-02-06 | 大日本住友製薬株式会社 | クロマン誘導体 |
-
2019
- 2019-03-19 ES ES19770755T patent/ES2941771T3/es active Active
- 2019-03-19 JP JP2020507833A patent/JP6733072B2/ja active Active
- 2019-03-19 MX MX2020009763A patent/MX2020009763A/es unknown
- 2019-03-19 PL PL19770755.7T patent/PL3770162T3/pl unknown
- 2019-03-19 WO PCT/JP2019/011439 patent/WO2019181939A1/ja unknown
- 2019-03-19 FI FIEP19770755.7T patent/FI3770162T3/fi active
- 2019-03-19 DK DK19770755.7T patent/DK3770162T3/da active
- 2019-03-19 TW TW108109362A patent/TW201941774A/zh unknown
- 2019-03-19 KR KR1020207029401A patent/KR20200135401A/ko not_active Application Discontinuation
- 2019-03-19 CN CN201980020335.0A patent/CN111886237A/zh active Pending
- 2019-03-19 SG SG11202007979UA patent/SG11202007979UA/en unknown
- 2019-03-19 AU AU2019239481A patent/AU2019239481B2/en active Active
- 2019-03-19 EP EP19770755.7A patent/EP3770162B1/en active Active
- 2019-03-19 HU HUE19770755A patent/HUE062256T2/hu unknown
- 2019-03-19 BR BR112020017481A patent/BR112020017481A8/pt unknown
- 2019-03-19 EA EA202092206A patent/EA202092206A1/ru unknown
- 2019-03-19 CA CA3092255A patent/CA3092255A1/en active Pending
- 2019-03-19 PT PT197707557T patent/PT3770162T/pt unknown
-
2020
- 2020-03-03 US US16/808,246 patent/US10807993B2/en active Active
- 2020-07-08 JP JP2020117566A patent/JP7247144B2/ja active Active
- 2020-07-31 US US16/944,482 patent/US11639357B2/en active Active
- 2020-09-18 PH PH12020551497A patent/PH12020551497A1/en unknown
-
2023
- 2023-03-15 JP JP2023040667A patent/JP7508620B2/ja active Active
- 2023-03-21 US US18/187,124 patent/US20230219970A1/en active Pending
- 2023-05-26 CY CY20231100250T patent/CY1126034T1/el unknown
-
2024
- 2024-06-19 JP JP2024098472A patent/JP2024123117A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124607A2 (es) | Arilquinazolinas | |
| CY1122933T1 (el) | Ενωσεις θειαζολοκαρβοξαμιδιων και πυριδινοκαρβοξαμιδιου χρησιμες ως αναστολεις κινασης ριμ | |
| CY1123177T1 (el) | Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη | |
| CR20120584A (es) | Derivados de n3-sustituido-n1-sulfonil-5-flúorpirimidinona | |
| AR098912A1 (es) | Inhibidores de syk | |
| CR20150491A (es) | 3-pirimidin-4-il oxazolidin -2- onas como inhibidores de idh mutante | |
| CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
| UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| NZ711101A (en) | Monocyclic pyridine derivative | |
| PE20160091A1 (es) | Derivados de ester de moduladores del receptor de androgeno y metodos para su uso | |
| PH12016501699A1 (en) | 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents | |
| DOP2011000258A (es) | Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata | |
| CR20120033A (es) | Derivados de 5-fluoro-2-oxopirimidina-1-(2h) carboxilato. | |
| MY179283A (en) | Antibacterial 2h-indazole derivatives | |
| PE20121429A1 (es) | Nuevo uso antitumoral de cabazitaxel | |
| BR112020017481A8 (pt) | Derivados de di-hidrocromeno | |
| CL2017000230A1 (es) | Composición adhesiva | |
| AR101704A1 (es) | Compuestos heterocíclicos fusionados | |
| BR112012021135A2 (pt) | microbicidas | |
| DOP2012000296A (es) | Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparación y su uso terapéutico | |
| PE20151295A1 (es) | Derivado de hidantoina | |
| DOP2011000296A (es) | Compuesto de pirazol | |
| GT201300044A (es) | Composiciones alguicidas sinergicas que incluyen derivados de hidrazona y cobre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO PHARMA CO., LTD. (JP) |
|
| B25G | Requested change of headquarter approved |
Owner name: SUMITOMO PHARMA CO., LTD. (JP) |